Dermira, Inc. (NASDAQ:DERM)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a report issued on Sunday. They presently have a $46.00 price target on the biopharmaceutical company’s stock. Needham & Company LLC’s price target points to a potential upside of 74.97% from the stock’s previous close.

DERM has been the topic of several other research reports. Zacks Investment Research raised shares of Dermira from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. Evercore ISI assumed coverage on shares of Dermira in a report on Thursday, June 29th. They issued an “outperform” rating and a $48.00 price target on the stock. BidaskClub raised shares of Dermira from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Cantor Fitzgerald assumed coverage on shares of Dermira in a report on Thursday, June 22nd. They issued an “overweight” rating and a $45.00 price target on the stock. Finally, Mizuho decreased their price target on shares of Dermira from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, May 25th. Four analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $44.40.

Shares of Dermira (NASDAQ:DERM) opened at 26.29 on Friday. The firm has a 50 day moving average price of $24.55 and a 200-day moving average price of $29.61. The firm’s market cap is $1.09 billion. Dermira has a one year low of $21.35 and a one year high of $38.75.

Dermira (NASDAQ:DERM) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.04). The firm had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.00 million. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. Analysts forecast that Dermira will post ($4.20) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/17/dermira-inc-derm-stock-rating-reaffirmed-by-needham-company-llc.html.

In related news, insider Eugene A. Bauer sold 2,500 shares of the stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $30.01, for a total value of $75,025.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Thomas G. Wiggans sold 5,000 shares of the stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $29.06, for a total value of $145,300.00. The disclosure for this sale can be found here. In the last three months, insiders sold 11,700 shares of company stock worth $337,537. 13.30% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its stake in Dermira by 15.6% in the second quarter. BlackRock Inc. now owns 3,922,253 shares of the biopharmaceutical company’s stock valued at $114,294,000 after acquiring an additional 529,405 shares during the last quarter. Jennison Associates LLC increased its stake in Dermira by 16.7% in the second quarter. Jennison Associates LLC now owns 2,632,994 shares of the biopharmaceutical company’s stock valued at $76,725,000 after acquiring an additional 377,554 shares during the last quarter. TimesSquare Capital Management LLC increased its stake in Dermira by 6.8% in the first quarter. TimesSquare Capital Management LLC now owns 2,588,661 shares of the biopharmaceutical company’s stock valued at $88,299,000 after acquiring an additional 164,950 shares during the last quarter. Vanguard Group Inc. increased its stake in Dermira by 9.8% in the second quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock valued at $40,735,000 after acquiring an additional 125,157 shares during the last quarter. Finally, Voya Investment Management LLC increased its stake in Dermira by 61.4% in the second quarter. Voya Investment Management LLC now owns 1,227,948 shares of the biopharmaceutical company’s stock valued at $35,783,000 after acquiring an additional 467,356 shares during the last quarter. 97.56% of the stock is currently owned by institutional investors and hedge funds.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.